Immunogenicity and Safety of Co-administration of Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine With 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years: A Randomized, Non-inferiority Trial

Journal:

Clinical Infectious Diseases

Published:

2026-04-13

DOI:

10.1093/cid/ciag250

Affiliations:

7

Authors:

11

Go to article

Institutions	Authors	Share
GlaxoSmithKline Belgium, Belgium	5.000000	0.45
Ghent University Hospital, Belgium	1.000000	0.09
AZ Sint-Maarten, Belgium	1.000000	0.09
Jupiter Medical Center, United States of America (USA)	1.000000	0.09
The Christ Hospital Health Network, United States of America (USA)	1.000000	0.09
GlaxoSmithKline R&D Bangalore, India	1.000000	0.09
GlaxoSmithKline USA, United States of America (USA)	1.000000	0.09

Interested in Medical Microbiology?